| Study Name | Description | Trial Category | Trial SubCategory |
|---|---|---|---|
| A032103 | The purpose of this study is to use central DNA testing to monitor recurrance in patients with urothelial cancer. You must have had a radical cysectomy and lymph node dissection with no evidence of residual cancer. | Cancer | Urothelial |
| EAY191-N5 | This study is for patient's who have HER2+ gynecologic cancers or other solid tumors. Cannot have breast cancer. You must have recurrent disease or progressed on treatment. | Cancer | Her2+ Solid Tumors |
| S2101 | This study is for patients with Stage III or IV, unresectable, recurrent, or metastatic melanoma. This study uses Nivolumab and Cabozantinib to treat patients. | Cancer | Melanoma |
| SOUL Music | This is a multicenter prospective trial with randomized and observational cohorts assessing patient-reported outcomes and unplanned healthcare utilization following ureteroscopic treatment of renal and ureteral stones, with placement versus omission of a ureteral stent. Eligible participants in the randomization trial will be randomized to ureteroscopy with stent placement or stent omission. Eligible participants that consent to the observational only cohort will complete surveys and the treating physicians will decide the treatment options for the participants. | Surgery | Urinary Stone Disease |
| S2013 | The purpose of this study is the look at the side effects of immunotherapy treatment. You must be starting immunotherapy alone not in combination with other treatments. You must have a solid tumor. | Cancer | Solid Tumors |
| Intuitive Surgical Ureter | The purpose of this study is to investigate whether the study drug may allow the surgeon to better see the ureters when using the da Vinci Surgical System for gynecological surgery. | Surgery | Gynecology |
| NRG-BR009 | The purpose of this study is treat breast cancer after surgery. You must have estrogen positive breast cancer and an oncotype score ≤25. This study looks at adding chemotherapy to the standard treatment of ovarian function suppression and aromatase inhibitor. | Cancer | Breast |
| GU012 | The purpose of this study is to compare standard immunotherapy with immunotherapy and radiation. You must be diagnosed with metastatic renal cell cancer and have not had surgery for this cancer. | Cancer | Metastatic Renal Cell |
| S2209 | This study is for frail-intermediately fit newly diagnosed multiple myeloma patients. Your current lab values will be used to determine if you qualify for this study. This study compares different chemo regimens to determine the effectiveness of them. | Cancer | Multiple Myeloma |
| A031701 | The purpose of this study is to compare standard or dose dense gemcitabine and cisplatin chemo. You must have been diagnosed with muscle invasive bladder cancer. | Cancer | Bladder |
| A031702 | The purpose of this study is to look at the effectineness of cabozantinib combined with nivolumab and ipilimubmab. You must be diagnosed with a rare genitourinary tumor of the kidney, bladder, ureters or penis. | Cancer | Rare Genitourinary |
| A031902 | The purpose of this study is to evaluate progression free survival and overall survival with the use of enzalutamide and rucaparib vs enzalutamide alone. You must be diagnosed with metastatic castration-resistant prostate cancer. This must be your first treatment for your metastatic cancer. | Cancer | Metastatic Prostate |
| A081801 (sub study A151216) | The purpose of this study is to compare disease free survival when adding immunotherapy to initial chemotherapy vs immunotherapy only in maintenance therapy. You must be diagnosed with stage 2 or stage 3 non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| A082002 | The purpose of this study is to determine in SBRT (stereotactic body radiation therapy) improves survival in advanced stage NSCLC. You must be diagnosed with stage 3 or 4 Non-Small Cell Lung Cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| A212102 | This is a study looking at determining effectiveness of a multicancer early dectection blood test. Participants are healthy subjects, those with a known cancer diagnosis, and those with high suspicion of cancer. | Cancer | All tumor types |
| EA5182 | This study is comparing Osimertinib and Bevacizumab vs Osimertinib alone as first-line treatment for patients with metastatic EGFR mutant Non-Small Cell Lung Cancer (NSCLC). You must be diagnosed with stage 3 or 4 NSCLC. | Cancer | Non-Small Cell Lung |
| EAA173 | The purpose of this study is determine if dararumumab enhances the effectiveness of revlimid in patients with smoldering myeloma. You must be diagnosed with asymptomatic high risk smoldering multiple myeloma. | Cancer | Smoldering Myeloma |
| EAA181 | The purpose of this study is to determine what consolidation regimen is most effective. Patients cannot get stem cell transplant until first relapse or later. You must have newly diagnosed multiple myeloma (MM). | Cancer | Multiple Myeloma |
| EAY191 ComboMATCH | The purpose of this study is to find targeted therapy for specific gene mutations in metastatic or advanced cancer. You must have progressed on standard of care treatment or have a cancer which has no standard of care treatment. If select mutations are found you may be eligible for a sub-study. | Cancer | Genomics |
| EAY191-A6 ComboMATCH | The purpose of this study is to see if adding Binimetinib in combination with FOLFOX is more effective treatment. You must be diagnosed with biliary tract cancer with a MAPK pathway gene mutation. | Cancer | Biliary |
| EAY191-E4 ComboMATCH | The purpose of this study is to determine the effectiveness of nilotinib and paclitaxel in patients with prior taxane treated solid tumors. You must have had at least one prior line of therapy in the metastatic setting. | Cancer | Solid Tumors |
| EAY191-N4 | The purpose of this study is to compare Selumetinib and Olaparib vs Selumetinib alone. You must be diagnosed with recurrent or persisent Ovarian or Endometiral cancer. Your cancer must have a RAS pathway mutation. | Cancer | Ovarian & Endometrial |
| EAY191-S3 ComboMATCH | The purpose of this study is to determine the effectiveness of Paclitaxel and Ipatasertib in patients who progressed within 6 months of taxane-based therapy. You must have a a AKT-Altered cancer. You must have a locally advanced, unresectable or metastatic cancer. | Cancer | Solid Tumors (non-breast) |
| ISPY 2 | This study uses the type of breast cancer you are diagnosed with to determine what treatment you are given. You must be diagnosed with stage 2 or stage 3 breast cancer. This study requires regular MRI's. | Cancer | Breast |
| NRG-GI008 | The purpose of this study to use blood draws looking at the tumor DNA in the blood to determine need for chemotherapy. You must be diagnosed with stage 3 colon cancer. | Cancer | Colon |
| NRG-GU010 | The purpose of this study is to determine if it is effective to use your genomic risk to determine the level of treatment you need. Those with a lower genomic risk get a de-intensified treatment and those with a higher risk get a intensified treatment. You must be diagnosed with unfavorable intermediate risk prostate cancer. | Cancer | Prostate |
| NRG-LU008 | The purpose of this study is to compare chemo and radiation followed by immunotherapy vs SBRT (stereotactic body radiation therapy) to primary tumor follwed by chemo and radiation then immunotherapy. You must be diagnosed with Stage 2 or 3 non-small cell lung cancer (NSCLC). | Cancer | Non-Small Cell Lung |
| S1922 | The purpose of this study is to determine the effectiveness of Ramucirumab and Paclitaxel vs Folfiri chemo. You must be diagnosed with metastatic or unresectable small bowel cancer. | Cancer | Small Bowel |
| S2001 | The purpose of this study is to determine the effectiveness of Olaparib + Prembrolizumab vs Olaparib alone. You must be diagnosed with metastatic pancreatic cancer with a BRCA1 or BRCA2 mutation. | Cancer | Pancreatic |
| S2200 | The purpose of this study is to compare treatment using cabozantinib with or without atezolizmab. You must be diagnosed with metastatic papillary renal cell cancer. | Cancer | Metastatic Renal Cell |
Unsupported Browser! This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.